N/A
ID
Bron
Verkorte titel
Aandoening
Mesalazine
Crohn's Disease
Relapse rate
Costs reduction
Ondersteuning
Department of Gastroenterology and Hepatology
University Medical Center Utrecht
P.O. Box 85500, 3508 GA Utrecht
Heidelberglaan 100, 3584 CX Utrecht
Tel.nr.: +31 887555555
Fax.nr.: +31 88 755 5533
E-mail: boldenbu@umcutrecht.nl
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
1. Proportion of patients who experience a clinical relapse during the 18 months follow-up period, defined as:<br>
A. CDAI score above 250 or a score between 150-250 in 3 consecutive weeks with an increase of at least 75 points above the baseline value;<br>
B. Need to perform surgery;<br>
C. Adjustment of CD-related therapy during follow-up, for example by the addition of steroids, infliximab, methotrexate, 6-mercaptopurine or azathioprine. <br>
2. Cost-effectiveness will be assessed.
Achtergrond van het onderzoek
N/A
Doel van het onderzoek
N/A
Onderzoeksopzet
0, 6, 12, 18 months of follow up .
Onderzoeksproduct en/of interventie
Patients will be randomized in a 1:1 ratio to 18 months of therapy receiving either mesalazine or no treatment. In case of mesalazine treatment, patients will continue their regular treatment. Physicians will be allowed to prescribe any brand of mesalazine (Asacol®, Pentasa®, Salofalk® or generic mesalazine). Dosing of Pentasa® and Salofalk® will be 3 gram once daily. Dosing of Asacol® will be 3.2 gram once daily.
Publiek
P.O. Box 85500, 3508 GA Utrecht
M.E. Valk, van der
Heidelberglaan 100
Utrecht 3584 CX
The Netherlands
+31 887557363
m.e.vandervalk-4@umcutrecht.nl
Wetenschappelijk
P.O. Box 85500, 3508 GA Utrecht
M.E. Valk, van der
Heidelberglaan 100
Utrecht 3584 CX
The Netherlands
+31 887557363
m.e.vandervalk-4@umcutrecht.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. 18 years or older;
2. Mesalazine maintenance therapy >1 year;
3. Quiescent disease (definition: CDAI <150);
4. Written informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Flare-up(s) of CD within 12 months preceding inclusion;
2. Treatment with prednisone, budesonide, infliximab, adalumimab of ceroluzimab within 12 months of inclusion;
3. Treatment with methotrexate, mercaptopurine or azathioprine, when initiated within 6 months prior to inclusion;
4. Extra-intestinal CD manifestations such as fistulas or pyoderma gangrenosum demanding induction therapy;
5. Treatment with enteral or parenteral feeding within 6 months prior to inclusion;
6. Treatment with metronidazole, ciprofloxacin, rectal steroids or rectal aminosalicylates within 12 months prior to inclusion;
7. Previous ileo-colorectal resection, such as small bowel resections >100 cm, total proctocolectomy, subtotal colectomy, colostomy or ileostomy;
8. Primary sclerosing cholangitis (PSC);
9. Hypersensitivity to mesalazine;
10. Disorders, which are likely to require systemic steroids (e.g. asthma);
11. Abnormalities in liver function tests (definition: 2x upper limit of normal value of ALAT. Normal values ALAT: > 45 U/L (men) of >35 U/L (women);
12. Abnormalities in kidney function tests (definition: creatinin > 120 ìmol/L (men) or
>103 ìmol/L (women);
13. Dysplasia or neoplasia of the colon;
14. Pregnant or lactating women.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1787 |
| NTR-old | NTR1897 |
| CCMO | NL29045.041.09 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON36566 |